← Leaderboards
Lupe G Salazar
University Of Washington
$2,699,874
Attributed
$3,942,529
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $710.8K · FY2005–13$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$3,942,529 · 9
By mechanism
P50$1,863,983 · 1
R01$847,881 · 1
K23$655,290 · 1
R21$513,448 · 1
M01$61,927 · 5
Top collaborators
- Mary L. Disis5 shared
- Ronald Swensen5 shared
Most similar at University Of Washington
Same institution · by research overlap
- Mary L. Disis$210,448,010
- Stephen R Plymate$6,213,858
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorT-LymphocyteImmunityImmune ResponseSafetyTumor AntigensCancer PatientCytokinePreventImmuneNeoplastic CellResponseImmunologicsActive ImmunizationProductionImmunosuppressive AgentsAntigen-Presenting CellsImmunogenicNeoplasm MetastasisSerumIn Complete RemissionMalignant Neoplasm Of OvaryCd8b1 GeneAnimal Model
Grant awards (20)
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$321,413
P50 · FY2013 · CA
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$347,224
P50 · FY2012 · CA
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$437,712
P50 · FY2011 · CA
Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Brea$273,122
R01 · FY2011 · CA · contact PI
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$369,911
P50 · FY2010 · CA
Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Brea$285,827
R01 · FY2010 · CA · contact PI
Vaccinating against IGFBP-2 to prevent ovarian cancer relapse$387,723
P50 · FY2009 · CA
Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Brea$288,932
R01 · FY2009 · CA · contact PI
Phase-I-II Study of DAB389 (ONTAK) in Patients with Adv. Refractory Breast Cancer$252,947
R21 · FY2007 · CA · contact PI
T Cell Memory After Immunization with a HER2 DNA Vaccine$131,058
K23 · FY2007 · CA · contact PI
PHASE I DOSE ESCALATION STUDY OF INTRAPERITONEAL ONTAK IN ADVANCED OVARIAN CANCE$8,373
M01 · FY2007 · RR · contact PI
PHASE I-II STUDY OF DENILEUKIN DIFTITOX (ONTAK) IN PATIENTS WITH ADVANCED REFRR$2,129
M01 · FY2007 · RR · contact PI
DEVELOPMENT OF HER-2/NEU (HER2) ICD MEMORY IMMUNITY AFTER VACCINATION$151
M01 · FY2007 · RR · contact PI
Phase-I-II Study of DAB389 (ONTAK) in Patients with Adv. Refractory Breast Cancer$260,501
R21 · FY2006 · CA · contact PI
T Cell Memory After Immunization with a HER2 DNA Vaccine$131,058
K23 · FY2006 · CA · contact PI
PHASE I DOSE ESCALATION STUDY OF INTRAPERITONEAL (IP) ONTAK IN OVARIAN CANCER$49,619
M01 · FY2006 · RR · contact PI
HER-2/NEU (HER2) ICD MEMORY IMMUNITY AFTER VACCINATION HER2-ICD$1,655
M01 · FY2006 · RR · contact PI
T Cell Memory After Immunization with a HER2 DNA Vaccine$131,058
K23 · FY2005 · CA
T Cell Memory After Immunization with a HER2 DNA Vaccine$131,058
K23 · FY2004 · CA
T Cell Memory After Immunization with a HER2 DNA Vaccine$131,058
K23 · FY2003 · CA